Nuclear factor kappa B may increase insight into the management of neuroinflammation and excitotoxicity in autism

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 6, 2011, Pages 781-783

  Ghanizadeh, Ahmad ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHIONINE SULFOXIMINE; MEVINOLIN; NEUROTENSIN; NITRIC OXIDE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

AUTISM; BIOLOGICAL ACTIVITY; CELL SURVIVAL; CYTOKINE PRODUCTION; DRUG TARGETING; EXCITOTOXICITY; GLIA CELL; HUMAN; INFLAMMATION; LETTER; NONHUMAN; ONCOGENE C KIT; OXIDATIVE STRESS; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; AUTISTIC DISORDER; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; NF-KAPPA B; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955802055     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.571212     Document Type: Letter

References (33)

1. Villagonzalo KA, Dodd S, Dean O, et al. Oxidative pathways as a drug target for the treatment of autism. Expert Opin Ther Targets 2010; 15 (12): 1301-10
2. Malik M, Sheikh AM, Wen G, et al. Expression of inflammatory cytokines, Bcl2 and cathepsin D are altered in lymphoblasts of autistic subjects. Immunobiology 2011;216(1-2):80-5
3. Sheikh AM, Li X, Wen G, et al. Cathepsin D and apoptosis related proteins are elevated in the brain of autistic subjects. Neuroscience 2010;165(2):363-70
4. Li X, Chauhan A, Sheikh AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009;207(1-2):111-16
5. Cohly HH, Panja A. Immunological findings in autism. Int Rev Neurobiol 2005;71:317-41 (Pubitemid 43580939)
6. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001;120(1-2):170-9 (Pubitemid 33016737)
7. Shinohe A, Hashimoto K, Nakamura K, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(8):1472-7 (Pubitemid 44634960)
8. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 1. Altern Ther Health Med 2008;14(6):46-53
9. Ghanizadeh A. May lovastatin target both autism and epilepsy? A novel hypothesized treatment. Epilepsy Behav 2011;20(2):422
10. Ghanizadeh A. Methionine sulfoximine may improve inflammation in autism, a novel hypothesized treatment for autism. Arch Med Res 2010;41(8):651-2
11. Ghanizadeh A. c-Kit+ cells transplantation as a new treatment for autism, a novel hypothesis with important research and clinical implication. J Autism Dev Disord 2011. [Epub ahead of print]
12. Ghanizadeh A. Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflammation 2010;7:58
13. Ghezzi P, Mennini T. Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuroimmunomodulation 2001;9(4):178-82 (Pubitemid 34195775)
14. Kaltschmidt B, Widera D, Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim Biophys Acta 2005;1745(3):287-99 (Pubitemid 41330783)
15. Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005;1034(1-2):11-24 (Pubitemid 40248516)
16. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4(7):702-10 (Pubitemid 32595408)
17. Leonoudakis D, Zhao P, Beattie EC. Rapid tumor necrosis factor alpha-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity. J Neurosci 2008;28(9):2119-30 (Pubitemid 351317637)
18. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007;85(10):2059-70 (Pubitemid 47172138)
19. Sitcheran R, Gupta P, Fisher PB, Baldwin AS. Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J 2005;24(3):510-20 (Pubitemid 40343253)
20. Ehrlich LC, Hu S, Peterson PK, Chao CC. IL-10 down-regulates human microglial IL-8 by inhibition of NF-kappaB activation. Neuroreport 1998;9(8):1723-6 (Pubitemid 28289174)
21. Chiarugi A. Characterization of the molecular events following impairment of NF-kappaB-driven transcription in neurons. Brain Res Mol Brain Res 2002;109(1-2):179-88 (Pubitemid 36078383)
22. Nurmi A, Lindsberg PJ, Koistinaho M, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 2004;35(4):987-91 (Pubitemid 38419815)
23. Sorg O, Horn TF, Yu N, et al. Inhibition of astrocyte glutamate uptake by reactive oxygen species: role of antioxidant enzymes. Mol Med 1997;3(7):431-40 (Pubitemid 27438767)
24. Ginis I, Hallenbeck JM, Liu J, et al. Tumor necrosis factor and reactive oxygen species cooperative cytotoxicity is mediated via inhibition of NF-kappaB. Mol Med 2000;6(12):1028-41
25. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997;20(6):252-8 (Pubitemid 27261456)
26. Pizzi M, Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol 2006;545(1):22-8
27. Teng FY, Tang BL. NF-kappaB signaling in neurite growth and neuronal survival. Rev Neurosci 2010;21(4):299-313
28. Fridmacher V, Kaltschmidt B, Goudeau B, et al. Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J Neurosci 2003;23(28):9403-8 (Pubitemid 37323040)
29. Mattson MP. NF-kappaB in the survival and plasticity of neurons. Neurochem Res 2005;30(6-7):883-93
30. Pizzi M, Sarnico I, Boroni F, et al. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ 2005;12(7):761-72 (Pubitemid 40945983)
31. Cruise L, Ho LK, Veitch K, et al. Kainate receptors activate NF-kappaB via MAP kinase in striatal neurones. Neuroreport 2000;11(2):395-8 (Pubitemid 30074656)
32. Guerrini L, Blasi F, Denis-Donini S. Synaptic activation of NF-kappa B by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA 1995;92(20):9077-81
33. Tolosa L, Caraballo-Miralles V, Olmos G, Llado J. TNF-alpha potentiates glutamate-induced spinal cord motoneuron death via NF-kappaB. Mol Cell Neurosci 2011;46(1):176-86